INNOSTAR ORD A (SHH) EQSW Exp: (688710) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of INNOSTAR ORD A (SHH) EQSW Exp: stock ¥10.21, price ¥86.00, that is 88.1% below the price, quality 29 out of 100. Rating: strongly overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 2, 2026.
How to read this chart
26‑month range ¥22.76 – ¥107.21 · fair‑value band ¥10.09 – ¥11.07 · the ¥86.00 price screens above the ¥10.21 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 2, 2026.
Follow INNOSTAR ORD A (SHH) EQSW Exp: in your weekly email
Every Wednesday you see whether INNOSTAR ORD A (SHH) EQSW Exp: is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shanghai InnoStar Bio-tech Co., Ltd. provides drug research and development services in China and internationally.
Show moreShow less
The company offers screening and discovery, nonclinical assessment stage, and clinical development stage services in the areas of chemical products, biologics, cell and gene therapeutics, radiopharmaceuticals, and traditional Chinese medicines.
The company was founded in 2010 and is based in Shanghai, China.
Stock analysis
INNOSTAR ORD A (SHH) EQSW Exp: (688710) currently trades at ¥86.00, while our model-based Fair Value estimate is ¥10.21, 88% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥11.89 per share, and 0 of the 6 models we run sit above the ¥86.00 price.
Bear case: the Asset-Based group reads lowest at ¥8.86, and 6 of the 6 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥10.09 (bear) to ¥11.07 (bull), the price of ¥86.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
INNOSTAR ORD A (SHH) EQSW Exp: reported revenue of 811M CNY in FY2025 versus 582M CNY in FY2021, a compound +8.7%/yr. Reported net income was −30.5M CNY in FY2025.
Key figures
Market cap 12.1B CNY (≈ $1.8B) Small · P/E ratio 156.4 · P/S ratio 11.8 · EPS (TTM) ¥0.5500 · Dividend yield 0.4% · Net margin 7.6% · Return on equity 3.1% · Return on assets (EBIT) 5.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and 111% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −88%, 688710 screens richer than that median.
Fair Value models
Bear¥10.09Fair Value ¥10.21Bull¥11.07
Price ¥86.00 · Downside -88.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.4701 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−28.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
18.7% (2021) → 2.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare INNOSTAR ORD A (SHH) EQSW Exp: with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 2/12 measures
Overall it trails its industry peers.
Valuation
Quality Score29 · Bottom 25%
Fair Value upside−88.1% · Bottom 25%
Profitability
Return on equity (12 months)3.1% · Below median
Return on assets−0.9% · Bottom 25%
Net margin (12 months)7.6% · Below median
Operating margin (12 months)27.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)64.4% · Top 25%
Dividend yield (12 months)0.4% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
P/E (12 months)156.4× · Priciest 25%
P/B5.22× · Pricier than median
P/S (12 months)11.81× · Priciest 25%
EV/EBITDA88.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)100· sector 34
PAST (return on equity)12· sector 41
HEALTH (low debt)0· sector 93
DIVIDEND (yield)7· sector 38
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "INNOSTAR ORD A (SHH) EQSW Exp: Fair Value". https://www.fairvalue-calculator.com/stock/688710
Frequently asked questions
Is INNOSTAR ORD A (SHH) EQSW Exp: (688710) overvalued or undervalued?
As of Nov 2, 2026, our model estimates a fair value of ¥10.21 versus a price of ¥86.00, about 88% lower (overvalued).
What is the fair value of 688710?
Our model-based fair value for INNOSTAR ORD A (SHH) EQSW Exp: is ¥10.21 (as of Nov 2, 2026), built from audited fundamentals. The current price: ¥86.00.
What is the quality score of 688710?
INNOSTAR ORD A (SHH) EQSW Exp: has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
Our model-based price target is the fair value of ¥10.21 (as of Nov 2, 2026) from 6 valuation models. Cautious scenario ¥10.09, optimistic scenario ¥11.07. It is a calculation from audited fundamentals, not an analyst target.
What is the INNOSTAR ORD A (SHH) EQSW Exp: stock forecast for 2026?
Our models put fair value at ¥10.21, about 88% lower versus a price of ¥86.00 (overvalued). Cautious scenario ¥10.09, optimistic scenario ¥11.07. The calculation is refreshed regularly with new filings.
What is the revenue of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
INNOSTAR ORD A (SHH) EQSW Exp: reported trailing-twelve-month revenue of about 1.0B CNY (latest available figure, as of Nov 2, 2026).
Does INNOSTAR ORD A (SHH) EQSW Exp: pay a dividend?
INNOSTAR ORD A (SHH) EQSW Exp: currently shows a dividend yield of 0.36% relative to its recent price (as of Nov 2, 2026).
How much is the dividend of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
INNOSTAR ORD A (SHH) EQSW Exp: has a dividend yield of 0.4%.
What is the intrinsic value of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For INNOSTAR ORD A (SHH) EQSW Exp: it is ¥10.21 per share (as of Nov 2, 2026), against a price of ¥86.00. It is the blended result of 6 valuation models in 4 families (Earnings-Based, Multiples, Asset-Based, Economic Profit).
Is INNOSTAR ORD A (SHH) EQSW Exp: stock overvalued or undervalued in 2026?
As of Nov 2, 2026, 688710 trades above its calculated fair value: price ¥86.00, fair value ¥10.21, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688710?
No. The price is what the market pays today (¥86.00); the fair value is what the company's own numbers justify (¥10.21). For INNOSTAR ORD A (SHH) EQSW Exp: the two are ¥75.79 per share apart. That gap is exactly why we show both numbers side by side.
How much is INNOSTAR ORD A (SHH) EQSW Exp: worth?
The market values INNOSTAR ORD A (SHH) EQSW Exp: at about 12.1B CNY (market capitalisation, as of Nov 2, 2026). Per share that is ¥86.00; our models calculate a fair value of ¥10.21 per share.
What do the bullish and bearish scenarios say about 688710?
Our models span a range for INNOSTAR ORD A (SHH) EQSW Exp:: cautious scenario ¥10.09, base ¥10.21, optimistic ¥11.07 per share (as of Nov 2, 2026, price ¥86.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688710?
INNOSTAR ORD A (SHH) EQSW Exp: trades at a price-to-earnings ratio of 156.4 (as of Nov 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥10.21 is built from several models across several years. Other multiples: P/B 5.2, P/S 11.8, EV/EBITDA 88.4.
How solid is the balance sheet of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
Balance-sheet figures for INNOSTAR ORD A (SHH) EQSW Exp: (as of Nov 2, 2026): return on equity 3.1%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 688710 from its 52-week high?
INNOSTAR ORD A (SHH) EQSW Exp: trades at ¥86.00, about 20% below its 52-week high of ¥107.21 and 111% above the low of ¥40.81 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥10.21 is for.
Which stocks are comparable to INNOSTAR ORD A (SHH) EQSW Exp:?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is INNOSTAR ORD A (SHH) EQSW Exp: stock attractive at the current price?
The data as of Nov 2, 2026: price ¥86.00, calculated fair value ¥10.21 (−88%), Quality Score 29/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688710 calculated?
We run INNOSTAR ORD A (SHH) EQSW Exp: through 6 models from 4 families: Earnings-Based, Multiples, Asset-Based, Economic Profit. Every model gets the same audited fundamentals; the fair value of ¥10.21 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. INNOSTAR ORD A (SHH) EQSW Exp: itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
The closing price on Nov 6, 2026 was ¥86.00. Our model-based fair value is ¥10.21, about 88% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with INNOSTAR ORD A (SHH) EQSW Exp: right now?
The price sits above even our optimistic bull case (¥11.07). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (¥10.09 to ¥11.07), unusually little disagreement for a valuation.
Key figures of INNOSTAR ORD A (SHH) EQSW Exp:
How large is the market capitalisation of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
The market capitalisation of INNOSTAR ORD A (SHH) EQSW Exp: is 12.1B CNY (≈ $1.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
The price-to-sales ratio of INNOSTAR ORD A (SHH) EQSW Exp: is 11.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
Earnings per share at INNOSTAR ORD A (SHH) EQSW Exp: are ¥0.5500 (price ÷ EPS = P/E 156.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
The dividend yield of INNOSTAR ORD A (SHH) EQSW Exp: is 0.4% (payout 55.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
The net margin of INNOSTAR ORD A (SHH) EQSW Exp: is 7.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
The return on equity (ROE) of INNOSTAR ORD A (SHH) EQSW Exp: is 3.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
On an EBIT basis the return on assets of INNOSTAR ORD A (SHH) EQSW Exp: is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
The operating margin of INNOSTAR ORD A (SHH) EQSW Exp: is 27.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
Revenue at INNOSTAR ORD A (SHH) EQSW Exp: is growing +64.4% versus a year earlier (3y avg −2.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
Earnings per share at INNOSTAR ORD A (SHH) EQSW Exp: are growing +161% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does INNOSTAR ORD A (SHH) EQSW Exp: (688710) generate?
The free cash flow of INNOSTAR ORD A (SHH) EQSW Exp: is −32.6M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch INNOSTAR ORD A (SHH) EQSW Exp: in the live analysis
One click puts INNOSTAR ORD A (SHH) EQSW Exp: on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 2, 2026